Over 500 Early Stage Investors Signed Up for RESI @ JPM

By Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series

Partnering is key. RESI is a dedicated partnering conference and will have 1400 meetings in one day. What is the salient difference between RESI and other conferences when it comes to partnering? RESI does not do the traditional “pay-to-pitch” on the podium to an unknown audience. We have found that the audience winds up being a mix of potential partners, other CEOs looking for competitive info and service providers wanting to sell their services. At RESI, when you sign up in our partnering system, investor profiles are highly detailed and tagged, allowing companies to perform searches and find the right investors and partners who are a fit for the companies’ stage of development and product set. This means you have a very high hit-rate on meetings because the RESI investors know that the firm making the request is a fit for their investment mandate.

At LSN, we vet all participating investors and do our best to ensure that those who attend are direct investors, not investment banks or broker-dealers. These global, cross-border, early-stage, from seed to series B, investors come to RESI to source technology assets for their pipelines and portfolios. RESI has helped over 350 companies raise over $500mm in the last three years. Click here to see who has already signed up.

AI, Remote Monitoring, Augmented Reality – Meet Israeli Digital Health Startups At RESI SF

By Tomer Epstein, Head of Medical Device & Digital Health, Israel Export Institute

With the RESI SF event during JPM week less than 3 weeks away the Israel Export Institute and the Israel Economic Mission to the West Coast are excited to partner with LSN and attend their annual event, RESI, one of the most prestigious investment events in the states, bringing over 500 investors under one roof.

We are bringing a delegation of 11 companies to join the RESI conference at JPM week. These companies are truly a good representation of Israel’s Digital Health Nation, showcasing technologies and solutions in: Artificial Intelligence, Personalized Medicine, Remote Monitoring, Decision Support Systems and more.

Israel’s Digital Health industry has its roots in a long history of using innovative communication technologies to improve healthcare delivery. With more than 25 years of expertise in implementing health IT, electronic medical records and business analytics; today, our Government is investing strongly in IT thus putting Israeli expertise in international demand.

The number of companies in the Israeli Digital Health sector has risen substantially in recent years, reaching more than 450 companies in 2018, all of which provide Digital Health services that can be delivered through the web or mobile and can improve the lives of millions of people around the world.

Below are the companies that are attending RESI SF as part of the Israeli delegation – if you are interested in learning more, reach out to them on the partnering platform. Also, if you would like to learn more about the startups and technologies being developed in Israel, stop by the Israel Export Institute and Israel Economic Mission to the West Coast table in the exhibit hall!

The Israel Export and International Cooperation Institute, supported by member firms, private sector bodies and the government of Israel, advances business relationships between Israeli exporters and overseas businesses and organizations. By providing a wide range of export-oriented services to Israeli companies and complementary services to the international business community, the Institute helps build successful joint ventures, strategic alliances and trade partnerships.

The Foreign Trade Administration (FTA) at the Israeli Ministry of Economy and Industry manages and supports Israel’s international trade and trade policy. Through our headquarters in Jerusalem together with over 45 economic and trade missions in key financial centers throughout the world, the FTA promotes Israel’s economy worldwide.

Meet the Delegation:

Augmedics is an Israeli startup company developing the xvision™ – an Augmented-Reality head-mounted display for spine surgery. xvision™ allows surgeons to see the patient’s anatomy through skin and tissue, as if they had “X-Ray Vision”, and to navigate their instruments securely without averting their eyes from their patient.

Datos helps healthcare organizations transform patient care, by better managing the overwhelming amount of digital data generated outside the hospital (e.g. Patient Generated Health Data), on a large scale at a fraction of current costs.

DayTwo is the leading Microbiome-Based Precision Medicine company, developing personalized nutrition, diagnostic, and therapeutic solutions using artificial intelligence and machine learning on microbial genomics, human traits, and disease.

Emedgene is the world’s first completely automated genetic interpretation platform. Emedgene uses NLP to ‘read’ new genetic research, and runs machine learning discovery algorithms on its always up-to-date knowledge base. By automating research, Emedgene can pinpoint causative genetic variants for a clear path to clinical decisions. Health organizations use Emedgene to scale personalized care.

The EyeControl is the first wearable, simple to use screen less medical device. The AI powered eye tracking technology enables locked-in/ventilated patients to communicate anytime, anywhere via eye movements. The EyeControl is improving the method of communication at home and in hospitals/rehabilitation centers between the patient and their medical staff/family.

IMedis AI is a medical imaging analysis company on a mission to revolutionize disease detection practices and improve clinical outcomes. Their first application examines all CT scans preformed and enables the detection of most common types of cancer precursors, thus improving early detection rates, survival rates and saving costs.

Medorion is developing a patient engagement platform to help Managed Care Organizations to efficiently carry-out digital persuasion campaigns. The platform uses behavioral based rules and AI to predict the best persuasion strategy for each member based on their clinical/claims history and executes this strategy through various digital channels including Facebook, Instagram, email, text messages and more.

Novotalk is an online, on-demand (asynchronous), self-directed tele therapy solution, which allows those with speech impairments to learn, practice, gain, and maintain comprehensible speech remotely, independently, and discretely. Novotalk removes the main barriers to superior and reliable therapy: accessibility, availability, and affordability.

Nucleai is an AI Healthcare startup in pathology domain aim to improve cancer diagnostics making it accurate, effective, accessible and efficient in order to treat patients better. Our core technology is AI based on advanced Machine Learning and Machine Vision algorithms.

Odoro – Digital Patient Access & Smart Scheduling Platform automates the patient access process in order to improve patient journey and increase utilization across multiple points of access – Self Scheduling, Intake, Call Center and Referral Management. Using a proprietary provider data management platform and patient engagement tools, Odoro unifies and streamlines patient related processes and perfect patient-provider matching for better care and higher patient satisfaction.

Uniper helps the elderly “thrive in place” in a dignified, connected, and fun way.  The company promotes active aging through its accessible, AI-based IoT technology. The platform enables the elderly to keep doing what they love, at home, without having to change habits or adopt new technologies or devices

Major Pharma Scouts Share Their Partnering Tips at RESI JPM

By Lucy Parkinson, VP of Investor Research, LSN

As big pharma companies continue to look outwards for innovative new therapeutics to add to their pipelines, many entrepreneurs are thinking about how to secure a partner even at the earliest stages of product development. At RESI, our Big Pharma panelists will inform the audience on how they source and vet new external opportunities, and what you should be doing to get their support as a partner.

Moderated by Chris Haskell (VP, Head of West Coast Innovation Center – Bayer), the panelists are:

  • Jessica Droge (Executive Director, Business Development – Amgen)
  • Niels Emmerich (Vice President, Global Head Search and Evaluation – AbbVie)
  • Kimberly Folander (Executive Director, Enabling Technologies, BD&L – Merck)
  • Chris Church (Manager, Partnering and Strategy, MedImmune – AstraZeneca)

These panelists will shed light on the process that big pharma goes through when sourcing early-stage assets and advise startups on how they can best make a case for themselves. Panelists will also explore various trends within the therapeutics marketplace, what assets are of interest to their company, and what they think will be big in the future. Join us at RESI to see this panel live.

Hot Investor Mandate: New York-Based Family Office Seeking Early-Stage Therapeutic Investment Opportunities

A family office, based in New York City, is looking to invest in therapeutics. The firm is most interested in companies that are IND ready through raising funds for Phase IIb clinical trials. The firm is willing to lead or co-invest, and will invest between $100K-$1.5M, depending on the round and the financial needs of the company. Historically, the firm has focused on investing in US and Israel.

The firm is interested primarily in therapeutics technologies. While agnostic to type of therapeutic, and open to most indications, much of the firm’s previous investments have been in oncology, cardiovascular or CNS related indications. The firm will invest as early as IND-ready companies, but no later than companies raising money for Phase IIb trials.

The firm has no specific company or management team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Venture Arm of Japanese Corporate Seeks Global, Strategic Investment Opportunities in Therapeutics, Devices, and Diagnostics Companies

A corporate venture arm of a large Japanese holding company is seeking to foster innovation across the group by investing in and partnering with strategic startups. In principle, the corporate venture capital arm is open to global opportunities and is geography and stage agnostic, but has specific preferences depending on the technology sector.

Healthcare/medical is one of the major focus areas of the holding company, and the corporate venture capital arm is interested therapeutics solutions such as solutions beyond the pill (digital therapeutics) and around the pill (delivery systems etc). Therapeutics areas of interest are CNS, Autoimmune diseases, metabolic diseases, regenerative medicine, Aging related solutions and Vaccines.

The corporate venture capital arm is also interested in diagnostics solutions based on genomics, metagenomics, metabolomics, healthcare ICT (biosensors etc), and medical big data. Furthermore, medical devices for wound care, bone cement and hospital related infection treatment is also is an area of interest and is open to all classes of medical devices including 510k and PMA.

The corporate venture capital arm has a close, collaborative relationship with other business arms within the holding company and can also present opportunities to them as appropriate.

The corporate venture arm is a flexible investor and does not require companies to have a Japan-centric angle. For medical device & digital therapeutics opportunities, the group does prefer technologies with strong promise in the US market. Through the firm’s strategic relationships, the group can help with Japan market entry and clinical trials, among other areas of needed support.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Healthcare-Focused Cross Border Firm Invests Up to $25M in High Potential Opportunities with China Angle

A healthcare-focused venture capital firm formed in 2017 manages 2 funds, a RMB denominated fund and a parallel USD fund. The firm generally seeks to make equity investments into emerging life science companies in seed and venture stages; however, the fund also considers commercial-stage companies, depending on the opportunity. The investment size of the USD fund ranges from $5 – $25 million. For the RMB fund, typical investment size is RMB $30-150 million. The firm currently focuses on China-based companies or overseas businesses with a China angle.

The firm is looking for new investment opportunities across a wide spectrum of life science sectors, including Therapeutics, Diagnostics, Biotech R&D Services, Medical Technology and Healthcare IT. The firm is agnostic to disease indications but is most interested in areas with large market potential, including Diabetes, Cardiovascular, Musculoskeletal System and Connective Tissue, Diseases of the Eye and Oncology. Rare diseases are generally less of interest. The firm is open to invest in both small molecules and biologics, and it looks for all classes of devices. The funds are most interested in companies in preclinical and early-clinical stage, but they are open to companies in late-clinical and growth stage, on a case-by-case basis.

The firm will only invest in private companies. The firm is looking to be an active investor, sometimes taking a board seat post-investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: California-Based VC Firm Invests in Early to Growth-Stage Healthcare Companies, With Strongest Interest in Digital Health Technologies

A California-based firm manages two active funds for both early-stage and growth investments. The firm is interested in investing in early-growth stage healthcare companies; the firm primarily invests in North America, but will consider opportunities worldwide. The firm typically makes Series A investments of ~$5-15M and Series B or later stage investments of ~$20-25 million. The firm is generally a lead investor, but will also enter syndicates with other major investors.

The firm is primarily interested in opportunities across digital health, transformational health IT, and biotech. In digital health, the firm focuses on technologies and services used by consumers or by enterprise/employers; in other categories, the firm has spent time, the firm’s interests include computational tools such as drug discovery tools and back-end solutions that can be used by companies in the clinical trial process during development of new drugs or devices. While the firm typically invests in companies that already have revenue, the firm may consider investing in prerevenue companies provided they have proven product-market fit by other means, such as securing key partnerships.

The firm invests primarily in US-based companies, but considers opportunities in other markets.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.